An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
Clinical trial NCT02253992 · TERMINATED
Trial details
- NCT number
- NCT02253992
- Sponsor
- Bristol-Myers Squibb
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-09-29
- Primary completion
- 2019-05-24
- Enrollment
- 232
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.